Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis

mBio

Volumn 3, Issue 5, 2012, Pages

  Lin, Lin ^a,b   Tan, Brandon ^a   Pantapalangkoor, Paul ^a   Ho, Tiffany ^a   Baquir, Beverlie ^a   Tomaras, Andrew ^c   Montgomery, Justin I ^c   Reilly, Usa ^c   Barbacci, Elsa G ^c   Hujer, Kristine ^d   Bonomo, Robert A ^d   Fernandez, Lucia ^e   Hancock, Robert E W ^e   Adams, Mark D ^f   French, Samuel W ^a,b   Buslon, Virgil S ^a   Spellberg, Brad ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f J CRAIG VENTER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868352677     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00312-12     Document Type: Article

References (61)

1. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal trans-duction. J. Biol. Chem. 274:10689-10692.
2. Hoshino K, et al. 1999. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749-3752.
3. Poltorak A, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
4. Bihl F, et al. 2003. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J. Immunol. 170:6141-6150.
5. Branger J, et al. 2004. Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. Infect. Immun. 72:788-794.
6. Lorenz E, Mira JP, Frees KL, Schwartz DA. 2002. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162:1028-1032.
7. Montes AH, et al. 2006. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin. Exp. Immunol. 143:404-413.
8. O'Brien GC, Wang JH, Redmond HP. 2005. Bacterial lipoprotein induces resistance to Gram-negative sepsis in TLR4-deficient mice via enhanced bacterial clearance. J. Immunol. 174:1020-1026.
9. Ragnarsdóttir B, et al. 2010. Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. PLoS One 5:e10734. http://dx.doi.org/10.1371 /journal.pone.0010734.
10. Ramphal R, et al. 2008. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide orflagellin. J. Immunol. 181:586-592.
11. van Westerloo DJ, et al. 2005. Toll-like receptor 4 deficiency and acute pancreatitis act similarly in reducing host defense during murine Esche-richia coli peritonitis. Crit. Care Med. 33:1036-1043.
12. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. 2009. Extensively drug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 15: 980-982.
13. Higgins PG, Dammhayn C, Hackel M, Seifert H. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65:233-238.
14. Perez F, et al. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
15. Dizbay M, Tunccan OG, Sezer BE, Hizel K. 2010. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand. J. Infect. Dis. 42:741-746.
16. Hidron AI, et al. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
17. Hoffmann MS, Eber MR, Laxminarayan R. 2010. Increasing resistance of Acinetobacter species toimipenem in United States hospitals, 1999-2006. Infect. Control Hosp. Epidemiol. 31:196-197.
18. Kallen AJ, Hidron AI, Patel J, Srinivasan A. 2010. Multidrug resistance among Gram-negative pathogens causing health care-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect. Control Hosp. Epidemiol. 31:528-531.
19. Lautenbach E, et al. 2009. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect. Control Hosp. Epidemiol. 30: 1186-1192.
20. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. 2010. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb. Drug Resist. 16:209-215.
21. Perez F, et al. 2010. Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility. Am. J. Infect. Control 38:63-65.
22. Rosenthal VD, et al. 2010. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am. J. Infect. Control 38:95-104.e2.
23. Adams MD, et al. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634.
24. Falagas ME, et al. 2008. Pandrug-resistant Klebsiella pneumoniae, Pseu-domonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents 32:450-454.
25. Rodriguez CH, et al. 2009. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn. Microbiol. Infect. Dis. 65:188-191.
26. Livermore DM, et al. 2010. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int. J. Antimicrob. Agents 35:19-24.
27. Park YK, et al. 2009. Independent emergence of colistin-resistant Acin-etobacter spp. isolates from Korea. Diagn. Microbiol. Infect. Dis. 64:43-51.
28. Valencia R, et al. 2009. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30:257-263.
29. Wang YF, Dowzicky MJ. 2010. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacte-remia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004-2008. Diagn. Microbiol. Infect. Dis. 68:73-79.
30. Vincent JL, et al. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323-2329.
31. Gordon NC, Wareham DW. 2009. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Che-mother. 63:775-780.
32. Lin MF, et al. 2009. Clinical features and molecular epidemiology of multidrug-resistant Acinetobacter calcoaceticus-A baumannii complex in a regional teaching hospital in Taiwan. Am. J. Infect. Control 37:e1-e3. http://dx.doi.org/10.1016/S0196-6553(09)00135-7.
33. Metan G, Sariguzel F, Sumerkan B. 2009. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur. J. Intern. Med. 20:540-544.
34. Park YK, et al. 2009. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg. Infect. Dis. 15: 1325-1327.
35. Sunenshine RH, et al. 2007. Multidrug-resistant Acinetobacter infection mortality rate and lengthofhospitalization. Emerg. Infect. Dis. 13:97-103.
36. Hernández-Torres A, et al. 2012. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality. Med. Clin. (Barc) 138:650-655.
37. Munoz-Price LS, et al. 2010. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: studyof a 2-state monoclonal outbreak. Infect. Control Hosp. Epidemiol. 31:1057-1062.
38. Tseng YC, et al. 2007. Prognosis of adult patients with bacteremia caused by extensively resistantAcinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 59:181-190.
39. García A, et al. 1999. Some immunological properties of lipopolysaccha-ride from Acinetobacter baumannii. J. Med. Microbiol. 48:479-483.
40. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. 2007. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J. Med. Microbiol. 56:165-171.
41. Knapp S, et al. 2006. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am. J. Respir. Crit. Care Med. 173:122-129.
42. Luo G, et al. 2012. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One 7:e29446. http://dx.doi.org/10.1371/journal.pone.0029446.
43. Arroyo LA, et al. 2011. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob. Agents Chemother. 55:3743-3751.
44. Barb AW, Zhou P. 2008. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. Curr. Pharm. Biotechnol. 9:9-15.
45. Montgomery JI, et al. 2012. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J. Med. Chem. 55:1662-1670.
46. López-Rojas R, et al. 2011. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J. Infect. Dis. 203:545-548.
47. de Breij A, et al. 2012. Differences in Acinetobacter baumannii strains and host innate immune response determine morbidity and mortality in experimental pneumonia. PLoS One 7:e30673. http://dx.doi.org/10.1371 /journal.pone.0030673.
48. Eveillard M, et al. 2010. The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. J. Infect. 60:154-161.
49. Casadevall A, Pirofski LA. 2003. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 1:17-24.
50. Henry R, et al. 2012. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-beta-1,6-N-acetylglucosamine. Antimicrob. Agents Chemother. 56:59-69.
51. Shepherd VL, Lee YC, Schlesinger PH, Stahl PD. 1981. L-Fucose-terminated glycoconjugates are recognized by pinocytosis receptors on macrophages. Proc. Natl. Acad. Sci. U. S. A. 78:1019-1022.
52. Moffatt JH, et al. 2010. Colistin resistance in Acinetobacter baumannii is mediated bycomplete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54:4971-4977.
53. Maragakis LL, Perl TM. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46: 1254-1263.
54. Seifert H, Strate A, Pulverer G. 1995. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 74:340-349.
55. Song JY, et al. 2011. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J. Med. Microbiol. 60(Pt 5):605-611.
56. Lin L, et al. 2009. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5:e1000703. http://dx.doi.org/10.1371/journal.ppat.1000703.
57. Spellberg B, et al. 2008. The anti-fungal rAls3p-N vaccine protects mice against the bacterium Staphylococcus aureus. Infect. Immun. 76: 4574-4580.
58. Luo G, et al. 2012. Diabetic murine models for Acinetobacter baumannii infection. J. Antimicrob. Chemother. 67:1439-1445.
59. McConnell MJ, Pachón J. 2010. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 29:1-5.
60. Baquir B, et al. 2012. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipogly-copeptide antibiotic oritavancin. Clin. Infect. Dis. 54(Suppl 3): S229-S232.
61. Piechaud M, Second L. 1951. Studies of 26 strains of Moraxella Iwoffi. Ann. Inst. Pasteur (Paris) 80:97-99.